Barclays downgrades Hologic on more cautious near-term outlook

Barclays analyst Jack Meehan downgraded Hologic to Equal Weight from Overweight and lowered his price target for the shares to $43 from $50. The analyst is more cautious around the near-term outlook for Hologic’s Diagnostics segment and potential for “heightened competitive activity” in 2019. Meehan also has “limited conviction” in CynoSure’s ability to accelerate and support mid-single digit growth overall. He views Hologic’s investment thesis and valuation as balanced at current share levels.
https://thefly.com/landingPageNews.php?id=2785711